Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates post-chemotherapy thrombocytopenia. The dose used post-chemotherapy is = 50 ng/kg/day s.c. Very little is known about the activity of IL-11 in bone marrow failure states. Our preliminary experience with IL-11 at doses of 50 ng/kg/day suggested that bone marrow failure patients developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We therefore initiated a study of low-dose IL-11 (10 jig/kg/d). Response criteria included doubling of platelets and rise to 50 x lO'/L or tripling of platelets and rise to 20 × 109/L. Sixteen pts are évaluable for response. Their median age was 58 years (range, 5 to 84 years). Six pts had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six of 16 pts (38%) showed a platelet response to IL-11 and two had a multilineage response (to IL-11 alone (N=l); to IL-11 + G-CSFand EPO (N=l)). Responders included 5 of 11 pts with myelodysplasia (MDS) and 1 of 4 patients with aplastic anemia (AA). Response duration was 12, 13, 14+, 22+, 25 and 30 weeks. Side-effects of IL-11 were mild (peripheral edema, N=7; conjunctival injection, N=7 or myalgia (N=l) (all grade 1). Seven pts had no side-effects. Our pilot study suggests that administration of low dose IL-11 (10μg/kg/day) can raise platelet counts, without significant toxicity, in selected thrombocytopenic patients with bone marrow failure.
|Original language||English (US)|
|Issue number||11 PART I|
|State||Published - 2000|
ASJC Scopus subject areas
- Cell Biology